Marinus Pharmaceuticals | MRNS - Interest Expense On Debt


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Marinus Pharmaceuticals

Marinus Pharmaceuticals reported $4.15M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.


Interest Expense On Debt Change
ALKERMES ALKS:US USD 5.29M 519K
Amgen AMGN:US USD 543M 128M
Biogen BIIB:US USD 62.5M 7.7M
Esperion Therapeutics ESPR:US USD 14.39M 58K
Gilead Sciences GILD:US USD 230M 3M
Incyte Corp INCY:US USD 469K 198K
Intercept Pharmaceuticals ICPT:US USD 2.81M 3K
Marinus Pharmaceuticals MRNS:US USD 4.15M 457K
Neurocrine Biosciences NBIX:US USD 1.1M 0
PTC Therapeutics PTCT:US USD 27.33M 1.43M
Regeneron Pharmaceuticals REGN:US USD 18M 600K
Sarepta Therapeutics SRPT:US USD 6.32M 365K
Supernus Pharmaceuticals SUPN:US USD 1.19M 22K
Vertex Pharmaceuticals VRTX:US USD 11.4M 200K